ClinicalTrials.gg
Enrolling by invitationNCT05600933Updated Oct 16, 2026

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

An observational study in Solid Tumors, Hematologic Malignancy and Gastrointestinal Cancer, sponsored by National Cancer Institute (NCI). Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by National Cancer Institute (NCI) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI) — 12 open to participants now, 33 under way, none of them phase 3. Hematologic Neoplasms · National Cancer Institute (NCI).

Started
2023
with 2 others
Observational
7 of 60
4 open now
Primary completion
2033-06
later than 29 of 32 live
Registered
55th of 60
by date

Among the 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI), this one is one of 3 that started in 2023, is one of 7 observational ones, reaches primary completion later than 29 of the 32 other live ones, and was the 55th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

12 of the 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

Many advances have been made in cancer treatments, but more research is needed. Comparing samples of cancerous tissue to samples of normal, noncancerous tissues may help find differences between them. These differences may help researchers find new ways to treat cancer.

Objective:

To collect tissues and blood samples from people with known or suspected cancer. The samples will be used to help identify new targets for cancer treatments.

Eligibility:

People aged 18 years and older with a known or suspected cancer that requires surgery or biopsy.

Design:

Participants will be screened. They will answer questions about their health. They can do this on the phone or in person.

Researchers will collect information from participants medical records. Data may include information about any prior or current cancers. Data about other medical conditions may also be collected.

Participants will have blood drawn. Some of the blood will be tested for HIV and hepatitis B and C. Some of the blood will be used for genetic research.

Participants will have tissue samples collected during surgeries or biopsies. These are procedures the participants would have had as part of their standard care. No new procedures will be done just for this study. Researchers may also seek out samples from prior procedures the participant had done.

Participants will remain in the study for 6 months. They may have blood drawn again. Researchers may also collect tissue samples from any procedures performed during that time.

Read the detailed description

Background:

  • Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer participants. A critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies.
  • The development of immuno-oncology therapeutics across a wide spectrum of malignancies has emphasized a need to understand the intratumoral immunologic landscape of metastatic cancer. The techniques of cultivating and examining tumor infiltrating lymphocytes developed in the Surgery Branch can be expanded and refined by the exploration of solid tumors.
  • The Surgery Branch, NCI has an interest in identifying novel molecular and biologic targets to facilitate the development of future cancer therapies for solid and hematologic malignancies. Through close collaborations with the Surgical Oncology Program and Thoracic Surgery Branch, our internal staff surgeons, and our medical oncology staff clinicians, we are uniquely positioned to acquire and perform important studies on solid tumor tissue and bone marrow to help identify therapeutic targets that may have significant clinical ramifications.

Objective:

To collect biologic samples from participants undergoing diagnostic or therapeutic interventions for known or suspected cancer for the purpose of identifying novel molecular and biologic therapeutic targets and studying the intratumoral immune landscape.

Eligibility:

Participants >=18 years of age with suspected or confirmed malignancies planning diagnostic or therapeutic intervention from which biologic samples may be obtained.

Design:

  • A tissue acquisition trial in which tissues will be obtained at the time of intervention.
  • Tissue and blood will be processed at the time of collection, stored and then transferred to the Surgery Branch Cell Production Facility for further processing.
  • No investigational therapy will be given.
  • It is anticipated that 1200 participants will be enrolled.
03

Conditions studied

  • Solid Tumors
  • Hematologic Malignancy
  • Gastrointestinal Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Melanoma
  • Pre-Malignancy
  • Lung Cancer

Keywords

  • Biologic Samples
  • Intratumoral Immunologic Landscape
  • Tumor Infiltrating Lymphocytes
  • Immuno-Oncology Therapeutics
  • Natural History
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects from both sexes and all racial/ethnic groups who are undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors or hematologic malignancies

Eligibility criteria

  • INCLUSION CRITERIA:
  • Age >= 18 years
  • Willing to undergo serologic testing for , and C
  • Participants who have a known or suspected cancer that requires surgery or as a part of the standard of care diagnosis, treatment and/or follow up.

Note: Participants will not be enrolled exclusively for the procurement of tissue samples.

-Able and willing to sign an document.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,200 participants (estimated)

Groups and cohorts

  • 1 - premalignant, primary or metastatic solid tumor

    Participants \>= 18 with a suspected or confirmed solid tumor malignancy that requires surgery or biopsy.

  • 2 - known or suspected hematologic malignancy

    Participants \>= 18 who have a known or suspected hematologic malignancy that requires surgery or biopsy.

06

What researchers measure

Primary outcomes

  1. To collect biologic samples from participants undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors and hematologic malignancies

    To collect biologic samples from participants undergoing diagnostic or therapeutic interventions for known or suspected cancer for the purpose of identifying novel molecular and biologic therapeutic targets and studying the intratumoral immune landscape.

    Time frame: At time of surgery or biopsy

Secondary outcomes

  1. To collect detailed history, demographic, treatment data, and perioperative findings.

    To collect detailed history, demographic, treatment data, and perioperative findings in order to categorize specimens.

    Time frame: At time of consent

07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

References and documents

Individual participant data

Plan to share: Yes — All IPD recorded in the medical record will be shared with intramural investigators upon request.@@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Clinical data will be available during the study and indefinitely.@@@@@@Genomic data will be available once genomic data are uploaded per protocol GDS plan for as long as database is active.

Access criteria: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.@@@@@@Genomic data will be made available via dbGaP through requests to the data custodians.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jun 2033, 121 months after the start.

Of 164 non-industry observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 121 months is above that.

Counting every sponsor, half of 186 studies reached it within 74 months; a quarter within 34 and three quarters within 322.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2022
First posted
Nov 1, 2022
StartActual
May 15, 2023
Primary completionEst.
Jun 15, 2033
CompletionEst.
Jun 15, 2033
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05600933
Responsible party
Sponsor
First posted
Nov 1, 2022
Start date
May 15, 2023
Primary completion
Jun 15, 2033 (estimated)
Completion
Jun 15, 2033 (estimated)
Last update
Oct 16, 2026

Study contacts

Steven A Rosenberg, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion